The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Quick Read Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss ...

Pfizer ( PFE +0.26%) and Eli Lilly ( LLY +1.80%) are two prominent names in healthcare that have focused on innovation and ...

Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Notably, the Huntsville site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...